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For years, a primary goal of tumor immunolo-
gists has been to trigger an anticancer response 
by the patient’s own immune system, directed 
largely at engaging the adaptive immune sys-
tem to mount a tumor-specifi  c response (1–3). 
However, a considerable body of evidence sug-
gests that nonlymphocytic immune cells also 
play an important role in eradicating tumors 
(4, 5). A new class of low molecular mass chemo-
therapeutic agents, vascular disrupting agents 
(VDAs), stimulate a variety of cell types, includ-
ing cells of the monocyte/macrophage lineage, 
to undergo morphological and functional changes 
that lead to cytokine release, increased vascular 
permeability, and rapid and sustained tumor vas-
cular collapse (6–9).
One class of VDAs includes fl  avone acetic 
acid and its derivatives, e.g., 5,6-dimethyl-
xanthenone-4-acetic acid (DMXAA). Although 
fl  avone acetic acid was found to exert extraordi-
nary antitumor eff  ects in mice, failed clinical trials 
revealed the species-specifi  c nature of this com-
pound (10, 11). In contrast, DMXAA is currently 
in advanced phase II clinical trials and has shown 
great promise in the treatment of a variety of 
malignancies (12, 13). The molecular mechanisms 
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Vascular disrupting agents (VDAs) represent a novel approach to the treatment of cancer, 
resulting in the collapse of tumor vasculature and tumor death. 5,6-dimethylxanthenone-4-
acetic acid (DMXAA) is a VDA currently in advanced phase II clinical trials, yet its precise 
mechanism of action is unknown despite extensive preclinical and clinical investigations. 
Our data demonstrate that DMXAA is a novel and specifi  c activator of the TANK-binding 
kinase 1 (TBK1)–interferon (IFN) regulatory factor 3 (IRF-3) signaling pathway. DMXAA 
treatment of primary mouse macrophages resulted in robust IRF-3 activation and  750-
fold increase in IFN-β mRNA, and in contrast to the potent Toll-like receptor 4 (TLR4) 
agonist lipopolysaccharide (LPS), signaling was independent of mitogen-activated protein 
kinase (MAPK) activation and elicited minimal nuclear factor κB–dependent gene expres-
sion. DMXAA-induced signaling was critically dependent on the IRF-3 kinase, TBK1, and 
IRF-3 but was myeloid differentiation factor 88–, Toll–interleukin 1 receptor domain–
containing adaptor inducing IFN-β–, IFN promoter-stimulator 1–, and inhibitor of κB 
kinase–independent, thus excluding all known TLRs and cytosolic helicase receptors. 
DMXAA pretreatment of mouse macrophages induced a state of tolerance to LPS and vice 
versa. In contrast to LPS stimulation, DMXAA-induced IRF-3 dimerization and IFN-β 
expression were inhibited by salicylic acid. These fi  ndings detail a novel pathway for TBK1-
mediated IRF-3 activation and provide new insights into the mechanism of this new class 
of chemotherapeutic drugs.
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of action of fl  avonoid VDAs are largely unknown; however, 
induction of cytokines has been implicated as a proximal event 
by which these agents induce tumor necrosis (14, 15).
Early studies revealed diff  erences in gene induction pat-
terns elicited in mouse macrophages stimulated by DMXAA 
versus the highly potent Toll-like receptor 4 (TLR4) agonist, 
Escherichia coli LPS (7, 16). Perera et al. reported that DMXAA 
potently induced a subset of LPS-inducible genes that in-
cluded both IFN-inducible protein 10 (IP-10) and IFN-β but 
poorly induced expression of proinfl  ammatory genes such 
as TNF-α (7). Although TNF-α was initially suspected to 
  induce tumor necrosis after DMXAA, TNF-α receptor–
  defi  cient mice displayed only a partially diminished capacity to 
reject tumor explants when treated with DMXAA, and serum 
from human subjects treated with DMXAA contained no de-
tectable TNF-α (17, 18). Jassar et al. later showed that macro-
phages are among the fi  rst cells to infi  ltrate the tumor after 
DMXAA treatment and are responsible for secreting large 
amounts of cytokines (19). Moreover, they express high levels 
of chemokines that may recruit cells into the tumor. Although 
the mechanism of action of DMXAA remains unknown, it is 
apparent from these studies that the macrophage response to 
DMXAA is important and requires further clarifi  cation.
Major advances have led to a detailed understanding of 
many of the signaling molecules involved in activation of the 
cells of the innate immune system (20). Among these, TLRs 
compose a major receptor family that enables pathogens to be 
sensed by the host. TLRs are expressed either on the surface 
or on an endosomal membrane of immune cells, where they 
detect conserved pathogen-associated molecular patterns 
(PAMPs). PAMP-induced oligomerization of TLRs recruits 
intracellular adaptor molecules to the C-terminal domain. 
Diff  erential engagement of PAMPs through the N terminus, 
coupled with diff  erential recruitment and utilization of indi-
vidual adaptor molecules by the diff  erent TLRs, provides the 
basis for the specifi  city with which cells respond to diff  erent 
PAMPs with diff  erent patterns of gene expression (21).
To date, four adaptors (myeloid diff  erentiation factor 88 
[MyD88], Toll–IL-1 resistance [TIR] domain–containing 
adaptor protein, TRIF-related adaptor molecule [TRAM], 
and TIR domain–containing adaptor inducing IFN-β [TRIF] 
[22–25]) have been associated with TLR signaling. MyD88 is 
absolutely required for the response to PAMPs detected by all 
known TLRs, with the exception of TLRs 3 and 4 (22, 26–29). 
In the case of TLR4, all four adaptors are used, and the intra-
cellular signaling cascade bifurcates into MyD88-dependent 
(i.e., MyD88 and TIR domain–containing adaptor protein 
mediated) and MyD88-independent (i.e., TRAM and TRIF 
mediated) arms (26). MyD88-dependent signaling leads to 
rapid recruitment of the family of IL-1R–associated kinases, 
phosphorylation of inhibitor of κB (IκB) α, nuclear translo-
cation of NF-κB, and expression of proinfl  ammatory genes 
such as TNF-α and IL-1β (20). In the case of TLR4, the 
MyD88-independent pathway utilizes TRAM to recruit 
TRIF that, in turn, recruits two noncannonical IκB kinases 
(IKKs), TANK-binding kinase 1 (TBK1) and IKKε (25, 30). 
Both phosphorylate the transcription factor IFN regulatory 
factor 3 (IRF-3) and result in a later wave of NF-κB transloca-
tion (31). Once phosphorylated, IRF-3 and NF-κB translocate 
to the nucleus, where they activate genes such as IFN-β.
In 2004, Yoneyama et al. described a TLR-independent 
pathway leading to IFN-β expression (32). Rather than a 
TLR, a cytosolic RNA helicase, retinoic acid–inducible gene I 
(RIG-I), detects double-stranded viral RNA via its helicase 
domain. RIG-I binds to an adaptor molecule, IFN-β promoter-
stimulator 1 (IPS-1; also known as MAVS, Cardif, and VISA), 
that leads to TBK1/IKKε activation, IRF-3 phosphorylation, 
and transcription of IFN-β (33). Another RIG-I–like molecule, 
melanoma diff  erentiation–associated gene 5, has also been 
previously described (34). RIG-I and melanoma diff  erentiation–
associated gene 5 distinguish between diff  erent RNA viruses, 
but both use IPS-1 (35, 36). Stetson et al. recently described 
yet another pathway leading to IRF-3 activation (37). Although 
the molecular sensor was not identifi  ed, cytosolic DNA 
was found to activate IRF-3 and induce IFN-β in the absence 
of detectable NF-κB or mitogen-activated protein kinase 
(MAPK) activation.
In this study, we detail a novel IFN-β–inducing pathway 
that is activated by DMXAA. DMXAA dramatically up-
regulates IRF-3–dependent gene expression in a TLR- and 
IPS-1–independent manner. The response was completely de-
pendent on both TBK1 and IRF-3 but elicited no detectable 
MAPK activation and minimal, delayed NF-κB DNA binding 
activity. Additionally, we show that although DMXAA does not 
lead to measurable IκBα degradation, it results in phosphory-
lation of p65 in a TBK1-dependent, but IKKβ-independent, 
manner. We also fi  nd that pretreatment of macrophages with 
either DMXAA or LPS induces a state of “cross-tolerance” for 
subsequent stimulation by DMXAA or LPS, suggesting shared 
utilization of signaling molecules. Interestingly, we also show 
that salicylic acid (SA) inhibits DMXAA- but not LPS-induced 
IRF-3 signaling in macrophages. Collectively, these data estab-
lish DMXAA as a novel, potent, and specifi  c activator of the 
TBK1–IRF-3 signaling cascade.
RESULTS
DMXAA is a specifi  c activator of IRF-3–mediated 
gene expression
It has been previously reported that DMXAA is a much more 
potent inducer of IFN-β protein and IP-10 mRNA in mouse 
macrophages than LPS, whereas LPS stimulation results in 
much higher levels of proinfl  ammatory cytokines, e.g., TNF-α 
and IL-1β (7). Fig. 1 confi  rms and extends these fi  ndings. Using 
real-time PCR to quantify mRNA expression of these genes 
in peritoneal exudate macrophages, DMXAA induced  10-
fold more IFN-β steady-state mRNA than LPS (Fig. 1 A). 
Although LPS stimulation led to the rapid disappearance of 
IκBα (Fig. 1 B) and NF-κB translocation (Fig. 1 C) in pri-
mary macrophages and the RAW 264.7 macrophage-like cell 
line, respectively, treatment with DMXAA had a minimal eff  ect 
on the level of IκBα protein and on NF-κB binding activity 
in EMSAs. Peak NF-κB activation in DMXAA-stimulated JEM VOL. 204, July 9, 2007  1561
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cells was observed at 120 min and was both delayed and less 
abundant than that seen in LPS-stimulated cells. Furthermore, 
under conditions in which LPS strongly activated p38, extra-
cellular signal-regulated kinase, and c-Jun N-terminal kinase 
MAPK signaling cascades within 15 min of treatment, treatment 
with DMXAA had no measurable eff  ect on these signaling 
intermediates over a 2-h time course (Fig. 1 D).
The partial overlap of gene expression profi  les for LPS- and 
DMXAA-stimulated macrophages led us to ask whether 
DMXAA might preferentially activate the MyD88-independent 
pathway via a unique interaction with TLR4, leading to acti-
vation of the transacting factor IRF-3. To address this pos-
sibility, macrophages from TLR4+/+ or background-matched 
TLR4−/− mice were stimulated with LPS or DMXAA, and 
gene expression was measured. Although LPS failed to induce 
TNF-α mRNA expression in the absence of TLR4 (P < 0.01), 
levels of TNF-α mRNA induced by DMXAA or the TLR3 
agonist poly I:C were not statistically diff  erent (Fig. 1 E). 
Collectively, these observations led us to hypothesize that 
DMXAA-induced signaling drives primarily on IRF-3, rather 
than NF-κB or the MAPK signaling cascades.
To extend these fi  ndings at the level of gene expression, 
macrophages were stimulated with medium only or DMXAA 
for 3 h, and mRNA was subjected to Aff  ymetrix microarray 
analysis. Of  14,000 genes analyzed, DMXAA resulted in a 
≥3-fold change in expression of 136 genes (110 and 26 genes 
were up-regulated or down-regulated, respectively), com-
pared with the response of medium-treated cells (microarray 
data have been deposited in the National Center for Biotech-
nology Information Gene Expression Omnibus under acces-
sion no. GSE7194; Table S1, available at http://www.jem
.org/cgi/content/full/jem.20061845/DC1). Because many of 
the genes that were modulated greater than or equal to 
threefold by DMXAA, such as Mx1, are known to be IFN-β–
  dependent, we also performed the same analysis in IFN-β−/− 
macrophages (38). A comparison of the results from these two 
strains revealed that 77 out of the 136 genes modulated by 
DMXAA in wild-type macrophages were IFN-β dependent 
(Table S1, WT/KO column), based on a threefold diff  erence. 
As TRIF is an adaptor required for IRF-3 activation after LPS 
stimulation (39), genes identifi  ed as poorly LPS inducible 
in TRIF−/− macrophages represent a reliable surrogate for 
Figure 1.  DMXAA preferentially induces IRF-3–mediated gene 
expression. (A) Peritoneal macrophages from C57BL/6 mice were stimu-
lated for 2 h with 100 ng/ml LPS or increasing concentrations of DMXAA, 
as shown. Total RNA was extracted and subjected to reverse transcription 
followed by quantitative real-time PCR, as described in Materials and 
methods. (B) Primary mouse macrophages were stimulated with medium 
alone, 100 ng/ml LPS, or 100 μg/ml DMXAA for the indicated times. Total 
protein was collected and subjected to SDS-PAGE, followed by Western 
blotting with anti-IκBα antibody. Protein molecular masses (in kD) appear 
at the right. (C) RAW 264.7 macrophages were stimulated with medium 
alone, 10 ng/ml LPS, or 1 mg/ml DMXAA for the indicated times. Nuclear 
extracts were prepared and subjected to EMSA with an NF-κB–specifi  c 
labeled oligonucleotide. (D) Peritoneal macrophages from C57BL/6 
mice were stimulated with medium alone, 100 ng/ml LPS, or 100 μg/ml 
DMXAA for the indicated times. Western blotting for activated MAPK was 
performed on whole-cell lysates. β-Actin was used as a loading control. 
  Protein masses (in kD) appear at the right. (E) Peritoneal macrophages 
from TLR4+/+ and TLR4−/− were stimulated with medium alone, 100 ng/ml 
LPS, or 100 μg/ml DMXAA for 2 h. Total RNA was collected and analyzed 
by quantitative real-time PCR, as in A. Results represent the mean ± SE 
for at least three independent experiments. **, P < 0.01.1562  DMXAA IS A SPECIFIC ACTIVATOR OF TBK1 | Roberts et al.
IRF-3–dependent gene induction. Many of the same genes 
induced by DMXAA in our microarray analysis were identi-
fi  ed as being poorly inducible by LPS in macrophages derived 
from TRIF-null mice (40); e.g., Rantes (Ccl5), Ifi  t1, Ccl4, and 
Oasl were shown by Hirotani et al. to be highly TRIF depen-
dent in LPS-treated macrophages. Thus, these data support 
the hypothesis that DMXAA preferentially induces IRF-3–
dependent genes.
DMXAA is a potent and specifi  c activator of TBK1
The IRF family of transcription factors has been shown to be 
integral to the regulation of the type I IFN response (41, 42). 
Phosphorylation of IRF-3 leads to the formation of IRF-3 
dimers, followed by the nuclear translocation and transcrip-
tion of genes such as IFN-β and regulated on activation, nor-
mal T expressed and secreted (RANTES) (43). To study the 
capacity of DMXAA to activate IRF-3, cell lysates from peri-
toneal macrophages exposed to either LPS or DMXAA were 
subjected to native PAGE to preserve fragile IRF-3 dimers. 
Proteins were transferred to polyvinylidene difl  uoride and 
subjected to Western blot analysis with an anti–IRF-3 anti-
body. Activated IRF-3 dimers were much more abundant 
and longer lived in DMXAA- versus LPS-stimulated macro-
phages (Fig. 2 A).
To demonstrate the ability of DMXAA to activate TBK1 
kinase activity in macrophages, TBK1 was immunoprecipi-
tated (using a highly specifi  c pAb raised against the C terminus 
of TBK1) from macrophages that had been stimulated for 
90 min with either LPS or DMXAA. Immunoprecipitated 
TBK1 complexes were subjected to an in vitro kinase assay using 
purifi  ed glutathione S transferase (GST)–IRF-3 (C-terminal aa 
380–427), and kinase activity was measured by autoradio-
graphy. To ensure comparability of levels of TBK1 in the immu-
noprecipitates, TBK1 was detected by Western blotting with 
an anti-TBK1 mAb. As seen in Fig. 2 B, DMXAA potently 
activated endogenous TBK1 kinase activity and induced clear 
Figure 2.  DMXAA is a potent and specifi  c activator of TBK1. 
(A) Peritoneal macrophages from C57BL/6 mice were stimulated with 
medium alone, 100 ng/ml LPS, or 100 μg/ml DMXAA for the indicated 
times. Total protein was collected and subjected to native PAGE, followed 
by Western blotting with an anti–IRF-3 antibody. (B) Bone marrow–
  derived macrophages were stimulated for 90 min with medium alone, 
200 ng/ml LPS, or 100 μg/ml DMXAA. Whole-cell lysates were subjected 
to immunoprecipitation with anti-TBK1 pAb, and immunoprecipitates 
were subjected to an in vitro kinase assay using the GST–C-terminal IRF-3 
wild-type or A7 mutant as the substrate, as described in Materials and 
methods. Levels of TBK1 in immunoprecipitates were examined by Western 
blotting using anti-TBK1 mAb. Recombinant TBK1 and IKKβ were also 
included as controls with GST–IRF-3 or IκBα substrates. Protein molecu-
lar mass appears at the right. Results shown are representative of four 
independent experiments. (C) Peritoneal macrophages from IRF-3+/+ and 
IRF-3−/− were exposed to medium alone or 100 μg/ml DMXAA for 24 h. 
Supernatants were collected, and cytokine concentrations were deter-
mined by Luminex bead assay. Results are representative of three 
  independent experiments. (D) TBK1+/+ and TBK1−/− MEFs were stimulated 
with medium alone, 100 ng/ml LPS, or 100 μg/ml DMXAA for 2 h. Total 
RNA was harvested and subjected to reverse transcription. Relative gene 
expression was measured by quantitative real-time PCR. Results represent 
the mean ± SE of at least three separate experiments. (E) TBK1+/+ and 
TBK1−/− MEFs were stimulated with 10 μg/ml LPS or 100 μg/ml DMXAA 
for 10 or 60 min. Whole-cell lysates were subjected to SDS-PAGE and 
probed with the indicated antibodies. Protein molecular masses appear 
at the right. Results are representative of three independent experiments. 
(F) IKKβ+/+ and IKKβ−/− MEFs were stimulated for 3 h with medium 
alone, 100 μg/ml DMXAA, 10 μg/ml or poly I:C in the presence of Fugene 6. 
IFN-β expression was measured by real-time PCR. Results are repre-
sentative of three independent experiments. (G) Peritoneal macrophages 
isolated from IKKε+/+ or IKKε−/− mice were stimulated with 100 μg/ml 
DMXAA for 24 h. Supernatants were collected, and RANTES expression 
was determined by ELISA. Results shown are mean ± SD for three 
 independent  experiments.JEM VOL. 204, July 9, 2007  1563
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phosphorylation of both TBK1 itself (left, top) and the wild-
type GST–IRF-3 substrate (left, bottom). Consistent with the 
results of the IRF-3 dimerization assay, DMXAA-induced 
TBK1 kinase activity was considerably more potent than that 
observed after stimulation with LPS. Importantly, a mutant 
version of IRF-3, in which seven serine/threonine residues 
were mutated to alanine (S385, S386, S396, S398, S402, T404, 
and S405®A; GST–IRF-3–A7), was not phosphorylated by 
endogenous TBK1 under conditions in which TBK1 auto-
phosphorylation was intact. In addition, an in vitro kinase assay 
revealed that recombinant TBK1 phosphorylated the wild-type 
GST-IRF-3, but not the A7 mutant, whereas recombinant 
IKKβ, which potently phosphorylated IκBα, failed to phos-
phorylate GST–IRF-3 measurably, consistent with previously 
published data (44). Collectively, these results clearly demon-
strate that DMXAA is a potent activator of the TBK1–IRF-3 
signaling axis.
To address the possibility that IRF-3 was required for 
activation of cells by DMXAA, peritoneal macrophages from 
wild-type and IRF-3−/− mice were cultured in medium only 
or DMXAA. Supernatants collected at 24 h were analyzed for 
cytokine production. Consistent with the robust IRF-3 acti-
vation observed in DMXAA-treated cells (Fig. 2, A and B), 
IRF-3−/− macrophages failed to produce RANTES, the 
product of a known IRF-3–dependent gene (45). Surprisingly, 
secretion of TNF-α was also reduced to background levels in 
IRF-3–defi  cient macrophages (Fig. 2 C). To evaluate further 
the role of activated IRF-3 in DMXAA-induced signaling, we 
exposed wild-type or TBK1-defi  cient mouse embryonic fi  bro-
blasts (MEFs) to medium only, LPS, or DMXAA and measured 
gene expression. Interestingly, we found that, in contrast to 
experiments with macrophages, DMXAA induced much 
more robust responses in MEFs than did LPS, an observation 
that is consistent with the diminished LPS sensitivity that has 
been observed in MEFs by others (46). In agreement with 
previous work (46), LPS-stimulated, TBK1−/− MEFs pro-
duced wild-type levels of RANTES and TNF-α mRNA 
(Fig. 2 D). However, TBK1−/− MEFs failed to express either 
RANTES or TNF-α mRNA in response to DMXAA. These 
results suggest that, in addition to being a potent activator of 
TBK1, DMXAA is critically dependent on both TBK1 and 
its downstream target, IRF-3, for gene expression.
Although TBK1 seems to function primarily as an IRF-3 
kinase, it has also been shown that, under certain circumstances, 
TBK1 may phosphorylate the NF-κB subunit p65 on serine 
536 (47). This phosphorylation event is believed to play a role 
in p65 transactivation, because cells lacking TBK1 show a de-
fect in NF-κB–dependent gene expression despite normal 
IκBα degradation and NF-κB binding activity (48). Because 
DMXAA is a relatively poor inducer of both IκBα degradation 
and NF-κB binding activity when compared with LPS (Fig. 1, 
B and C) but has previously been shown to induce NF-κB–
  dependent gene expression (49), we sought to examine the phos-
phorylation status of p65 in LPS versus DMXAA-stimulated 
cells. In wild-type MEFs, LPS-induced phosphorylation of p65 
on S536 was observed at 10 min and peaked at 60 min, whereas 
DMXAA-induced p65 phosphorylation was undetectable at 
10 min but measurable at 60 min. Surprisingly, in contrast to 
LPS-induced phospho-p65, DMXAA-induced p65 phosphor-
ylation was ablated in TBK1-null MEFs at 60 min (Fig. 2 E). 
In further support of the assertion that DMXAA is a specifi  c 
activator of the TBK1–IRF-3 signaling axis, we tested the abil-
ity of DMXAA to induce IFN-β in MEFs defi  cient in the 
NF-κB–activating kinase IKKβ. Remarkably, under conditions 
in which transfected poly I:C, a known inducer of NF-κB 
(32), failed to activate IFN-β expression in IKKβ-null MEFs, 
DMXAA-induced IFN-β was found to be independent of 
IKKβ (Fig. 2 F). Collectively, these fi  ndings suggest that 
DMXAA activates NF-κB in a manner that is both indepen-
dent of IKKβ but completely dependent on TBK1.
To address a possible role for IKKε, the only other IRF-3 
kinase identifi  ed thus far, in DMXAA-induced signaling, we 
compared the response of macrophages isolated from wild-
type and IKKε-defi  cient mice after treatment with DMXAA. 
Induction of RANTES protein was not inhibited in IKKε-
null cells (Fig. 2 G). Collectively, these data support the con-
clusion that DMXAA activates a pathway that is dependent 
on both IRF-3 and TBK1 but is independent of both IKKβ 
and IKKε.
DMXAA-induced gene expression is TLR- 
and IPS-1–independent
Because all known TLRs, with the exception of TLRs 3 and 
4, have an absolute requirement for MyD88 to induce gene 
expression, we tested the ability of DMXAA to induce signal-
ing in MyD88−/− macrophages. Consistent with previous 
  reports (22, 26), LPS-induced IFN-β mRNA and protein (Fig. 
3 A) were not signifi  cantly decreased by MyD88 defi  ciency, 
whereas levels of TNF-α were dramatically inhibited in the 
MyD88−/− macrophages (Fig. 3 B). In contrast, DMXAA-
induced IFN-β and TNF-α mRNA and protein were not 
signifi  cantly diff  erent in wild-type and MyD88−/− cells. Thus, 
DMXAA-induced gene expression is MyD88 independent.
TLRs 3 and 4 share the ability to activate IRF-3 and 
induce IFN-β via another adaptor, TRIF. To directly address 
the possibility that DMXAA utilizes the MyD88-independent 
pathway mediated by TRIF, background-matched, wild-
type, and TRIF−/− MEFs were stimulated with DMXAA or 
the TLR3 agonist poly I:C. Fig. 3 C illustrates that compared 
with poly I:C, a known TRIF-dependent inducer of RANTES 
(25), DMXAA-induced RANTES was unaff  ected by the 
absence of TRIF. In further support of the conclusion that 
DMXAA does not require any known TLR for activity, macro-
phages defi  cient in both MyD88 and TRIF responded to 
DMXAA by making RANTES protein at a level that was not 
statistically diff  erent from that made by wild-type cells, whereas 
LPS-induced RANTES was reduced to baseline levels in 
TRIF−/−/MyD88−/−-defi  cient macrophages (Fig. 3 D). Because 
DMXAA is, therefore, neither MyD88- nor TRIF-dependent, 
these data indicate that none of the known TLRs serve as a 
receptor for DMXAA, because all require MyD88 and/or TRIF 
to mediate signaling.1564  DMXAA IS A SPECIFIC ACTIVATOR OF TBK1 | Roberts et al.
Because our data implied that DMXAA does not require 
known TLRs to activate IRF-3–inducible genes, we postulated 
that DMXAA might engage the recently identifi  ed cytosolic 
RNA helicases RIG-I or Mda5. Therefore, we fi  rst examined 
the response of background-matched wild-type and RIG-I−/− 
MEFs, and in accordance with previous work (50), the latter 
failed to respond to Newcastle disease virus (unpublished data). 
However, when stimulated with LPS or DMXAA, RANTES 
secretion was intact in the RIG-I−/− MEFs (Fig. 3 E). Thus, 
DMXAA-activated IRF-3 and IRF-3–dependent gene expres-
sion is RIG-I independent.
Both RIG-I and another RNA helicase, Mda5, use a 
downstream adaptor molecule, IPS-1, to induce gene expres-
sion. To determine if Mda5 might contribute to DMXAA-
induced signaling, we stimulated IPS-1–defi  cient MEFs with 
either LPS, DMXAA, or cytosolic (i.e., transfected) poly I:C. 
As shown in Fig. 3 F, under conditions in which the cytosolic 
poly I:C–induced RANTES expression was reduced to near-
background levels, DMXAA- and LPS-induced RANTES 
were unaff  ected. Collectively, the results in Fig. 3 indicate 
that DMXAA does not require any known TLR or RNA 
helicase for a cellular response.
LPS and DMXAA induce cross-tolerance
Endotoxin tolerance is a poorly understood phenomenon that 
has been described as a transient state of LPS hyporesponsiveness 
induced by prior exposure to a low level of LPS both in vitro 
in macrophages and in vivo. Moreover, “TLR heterotolerance” 
can be induced (i.e., prior exposure to one TLR agonist 
diminishes responsiveness to challenge through a distinct TLR 
[51]), and LPS and IL-1β “cross-tolerize” (52). The ability to 
induce heterotolerance or cross-tolerance has been suggested 
to be caused by the disruption of shared signaling pathway 
molecules between distinct receptor systems (51). To deter-
mine if LPS and DMXAA can cross-tolerize, peritoneal macro-
phages were pretreated with medium, LPS, or DMXAA. 
After 24 h, cells were washed and restimulated for 1 h with 
LPS or DMXAA. Protein was subjected to native PAGE and 
Western blotting for IRF-3, and IFN-β mRNA was quantifi  ed 
by real-time PCR.
LPS pretreatment of cells resulted in a diminished response 
to a second LPS exposure, both at the level of IFN-β mRNA 
(Fig. 4 A) and IRF-3 dimerization (Fig. 4 B), indicating that 
classical endotoxin tolerance was induced. LPS pretreatment 
of macrophages also mitigated the subsequent response to 
DMXAA. Conversely, pretreatment with DMXAA induced 
a state of refractoriness to restimulation with either LPS or 
DMXAA. These results suggest that signaling elements ren-
dered hypoactive by pretreatment with LPS are also used by 
DMXAA and vice versa.
SA selectively inhibits DMXAA-induced IFN-𝗃
SA has been reported to inhibit IKKβ (53, 54) and has been 
shown to inhibit TNF-α in human mononuclear cells when 
DMXAA is combined with anti-CD14 antibodies or deacyl-
ated LPS (8). Because IRF-3–dependent gene expression had 
not been shown previously to be SA sensitive, we sought to test 
the hypothesis that SA might down-regulate DMXAA-induced 
IFN-β expression. To address this hypothesis, peritoneal macro-
phages were pretreated with increasing concentrations of SA, 
followed by stimulation with LPS or DMXAA. Fig. 5 A shows 
that SA dramatically reduced DMXAA-induced IFN-β expres-
sion, whereas LPS-induced IFN-β mRNA expression was 
essentially unaff  ected. Furthermore, pretreatment of macro-
phages with SA also inhibited both IRF-3 dimer formation and 
phosphorylation of S396 of IRF-3 in response to DMXAA but 
not LPS (Fig. 5 B). In toto, these data support the hypothesis that 
Figure 3.  DMXAA signaling is TLR- and IPS-1–independent. 
(A and B) Peritoneal macrophages from MyD88+/+ or MyD88−/− mice 
were stimulated with 100 ng/ml LPS or 100 μg/ml DMXAA. After a 2-h 
incubation (left), total RNA was collected, and gene expression was asses-
sed by quantitative real-time PCR. ELISA results (right) were generated 
from supernatants collected 24 h after exposure to medium, 100 ng/ml 
LPS, or 100 μg/ml DMXAA. (C) TRIF+/+ and TRIF−/− MEFs were stimulated 
with 100 μg/ml DMXAA or 100 μg/ml poly I:C for 24 h. Supernatants 
were collected, and RANTES levels were measured by ELISA. (D) Wild-type 
or MyD88−/−/TRIF−/− peritoneal macrophages were stimulated with 
100 mg/ml DMXAA, 100 ng/ml LPS, or 200 hemagglutination U/ml Sendai 
virus for 24 h. RANTES expression was measured by ELISA. RIG-I+/+ and 
RIG-I−/− (E) or IPS-1+/+ and IPS-1−/− (F) MEFs were treated for 24 h with 
medium alone, 1 μg/ml LPS, 100 μg/ml DMXAA, or 10 μg/ml poly I:C in 
the presence of Fugene 6. Supernatants were collected, and RANTES levels 
were assessed by ELISA. Results shown are the mean ± SE of at least 
three independent experiments. **, P < 0.01; ***, P < 0.001.JEM VOL. 204, July 9, 2007  1565
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DMXAA activates a unique signaling pathway leading to the 
TBK1-dependent induction of IRF-3– and phospho-p65–
mediated gene expression.
D  I  S  C  U  S  S  I  O  N 
DMXAA is currently in advanced phase II clinical trials for 
effi   cacy against lung, prostate, and ovarian cancers. It is well 
tolerated at therapeutic doses (13, 55) and induces measurable 
changes in tumor blood fl  ow within 30 min of i.v. adminis-
tration (56). In this paper, we have detailed as of yet un-
explored aspects of the fl  avonoid class of VDAs: the dramatic 
up-regulation of IFN-β by DMXAA and the demonstration 
of the TBK1–IRF-3 axis as an absolute requirement for gene 
induction by DMXAA in macrophages and MEFs. The link 
between this promising new chemotherapeutic agent and its 
remarkable capacity to induce IFN-β provides a new rationale 
for exploring the complex role played by type I IFNs in the 
host against cancer.
A previous study (7) showed that stimulation of mouse 
macrophages with DMXAA led to the rapid up-regulation of 
IFN-β, fi  ndings confi  rmed and extended by our data. Impor-
tantly, the robust expression of IFN-β was not accompanied 
by activation of the MAPKs and led to NF-κB activation at 
dramatically reduced levels and delayed kinetics compared 
with LPS (Fig. 1). Early studies performed by Maniatis et al. 
detailed the assembly of a multiprotein complex termed the 
“enhanceosome” (57). The components of the enhanceosome 
(NF-κB, IRF-3, IRF-7, and ATF2–c-Jun) bind to adjacent 
regulatory elements in the IFN-β promoter termed positive 
regulatory domain (PRD) II, PRD III-I, and PRD IV, re-
spectively, and there is compelling evidence that suggests 
LPS-induced IFN-β is driven by the assembly of the enhan-
ceosome (58). Indeed, after treatment with LPS, we observed 
robust activation of all three members of the enhanceosome, 
and this activation coincided with IFN-β gene transactivation. 
In contrast, DMXAA-induced activation of both NF-κB and 
the MAPK cascades was considerably less pronounced than 
that observed in LPS-stimulated cells despite a more potent 
induction of IFN-β. Moreover, IKKβ-defi  cient MEFs re-
spond normally to DMXAA by producing wild-type levels of 
IFN-β mRNA (Fig. 2 F), suggesting that DMXAA does not 
use the classical NF-κB pathway upstream of IFN-β transcrip-
tion. Interestingly, however, DMXAA induces phosphoryla-
tion of p65 at S536 at levels comparable with those achieved 
with LPS (Fig. 2 E). Phosphorylation of S536 has been sug-
gested by others to enhance the transactiva  tion potential of the 
p65 subunit (for review see reference 59). Thus, phosphoryla-
tion of p65 on S536 may increase the “gain” of NF-κB, pro-
viding a plausible explanation for DMXAA’s ability to induce 
robust IFN-β expression despite very little IκBα degradation. 
In other words, it is possible that the relatively small amount 
of activated NF-κB available after treatment with DMXAA is 
Figure 4.  DMXAA pretreatment of macrophages induces a state 
of refractoriness upon reexposure to either LPS or DMXAA. Total RNA 
(A) or protein (B) from C57BL/6 peritoneal macrophages pretreated with 
medium alone, 100 ng/ml LPS, or 100 μg/ml DMXAA, washed, and re-
stimulated with medium, LPS, or DMXAA was collected and subjected to 
quantitative real-time PCR (A) or native PAGE, followed by Western blot-
ting for IRF-3 (B). Results shown are the mean ± SE of one representative 
experiment (n = 3).
Figure 5.  Sensitivity of DMXAA-induced gene expression and IRF-3 
activation to SA. (A) Peritoneal macrophages from C57BL/6 mice were 
pretreated with medium alone or increasing concentrations of SA for 1 h 
and stimulated with LPS or DMXAA for an additional 2 h. Total RNA was 
harvested, and gene expression was assessed by quantitative PCR. Results 
represent the mean ± SE of at least three separate experiments. **, P < 
0.01; ***, P < 0.001. (B) Macrophages were pretreated with or without 16 mM 
SA for 1 h and stimulated with 10 or 100 ng/ml LPS, or 10 or 100 μg/ml 
DMXAA, for an additional 1 h. Total protein was harvested and subjected 
to native PAGE (top) or SDS-PAGE (bottom), followed by Western 
blot analysis for IRF-3 and anti–phospho–IRF-3, respectively. Protein 
  molecular mass appears at the right. Results shown are representative 
of three independent experiments.1566  DMXAA IS A SPECIFIC ACTIVATOR OF TBK1 | Roberts et al.
suffi   cient to complete the IFN-β enhanceosome or is compen-
sated for by its increased transactivation potential. Finally, in 
contrast to LPS treatment, DMXAA-induced p65 phosphory-
lation is abolished in TBK1-defi  cient MEFs, providing further 
support for the conclusion that DMXAA is a novel and specifi  c 
activator of the TBK1–IRF-3 signaling axis.
This claim is further supported by our results derived 
from TBK1- and IRF-3–defi  cient mice. DMXAA-induced 
expression of RANTES, a heavily IRF-3–dependent gene 
(45), was observed to be completely dependent on the TBK1–
IRF-3 axis (Fig. 2). Surprisingly, this dependence on TBK1 
and IRF-3 extended to genes not normally considered to be 
dependent on IRF-3, such as TNF-α. Under conditions 
where LPS-induced TNF-α was unaff  ected, IRF-3–defi  cient 
cells failed to induce TNF-α mRNA in response to DMXAA. 
This suggests that DMXAA-induced TNF-α expression is 
strictly IRF-3–dependent. Although it is possible that the 
failure of DMXAA-treated TBK1-null MEFs to phosphory-
late p65 contributes to reduced availability of NF-κB for 
induction of genes such as TNF-α, our DNA microarray data 
(Table S1) revealed that TNF-α expression in response to 
DMXAA is diminished in IFN-β–null macrophages. These 
results support the alternative possibility that TNF-α is part of 
an IFN-β–dependent “second wave” of gene expression after 
DMXAA treatment.
Although the role of type I IFN in both tumor immunity 
and the treatment of cancer has been studied for decades, the 
direct involvement of IRF-3 is considerably less well under-
stood. However, it was recently shown that IRF-3 drives 
the up-regulation of TNF-related apoptosis-inducing ligand 
in virally infected cells, as well as directing cells into p53-
  dependent cell-cycle arrest and senescence (60, 61). Perhaps 
even more pertinent to the current work are recent studies by 
Duguay et al. with human IRF-3–expressing B16 melanoma 
tumors (62). In their study, tumors expressing IRF-3 grew 
more slowly than those that had been mock transduced. 
Furthermore, the IRF-3–positive tumors demonstrated a robust 
up-regulation of a variety of chemokines in vivo, including 
RANTES, macrophage infl  ammatory protein 1β, and IP-10. 
Accordingly, IRF-3–expressing tumors recruited consider-
ably more neutrophils and lymphocytes and showed signs of 
retarded tumor growth, including a larger capsule, fewer 
blood vessels, and areas of necrosis. Importantly, the results 
reported by Duguay et al. mirror those of Jassar et al. (19) in 
which implanted tumors showed dramatically increased levels 
of IP-10 and RANTES, as well as necrosis, after i.v. DMXAA 
administration. The results presented herein provide a plausible 
link between the direct antitumor results of IRF-3 overexpres-
sion and those after treatment with DMXAA.
The ability of DMXAA to activate IRF-3 and induce 
IRF-3–mediated gene expression led us to address the involve-
ment of established pattern recognition receptors in DMXAA 
signaling. DMXAA-induced signaling was found to be intact in 
both MyD88−/−/TRIF−/− and IPS-1−/− cells, thereby elim-
inating the possibility of involvement of all known TLRs and 
RNA helicases. However, a third non–TLR-dependent pathway 
leading to expression of IFN-β was recently described by Stetson 
et al. in which the presence of cytosolic, non–CpG-containing 
DNA stimulated high levels of type I IFN (37). In that study, 
however, the molecular sensor of the stimulus was not iden-
tifi  ed. Notably, the authors reported that the type I IFNs 
induced by cytosolic DNA were not accompanied by either 
MAPK activation or NF-κB translocation, consistent with our 
observations. With a molecular mass of 304 daltons, DMXAA is 
much smaller than the DNA used in that study. However, 
it remains possible that DMXAA may engage the molecular 
sensor or a downstream signaling component of this novel 
pathway to initiate signaling leading to IRF-3 activation. Studies 
to identify the nature of this sensor are currently in progress.
Previous studies have shown that pretreatment of macro-
phages or mice with LPS results in a transient desensitization 
to subsequent stimulation by LPS, other TLR agonists, or 
IL-1β. The mechanisms that underlie tolerance are clearly 
multifactorial; however, interference with signal transduction 
appears to be a common mechanism (51, 63). DMXAA, like 
LPS, induced a state of tolerance in macrophages to sub-
sequent stimulation with either DMXAA or LPS, as indicated 
by inhibition of not only IFN-β gene expression but also 
IRF-3 dimer formation (Fig. 4). This implies that disrupted 
signaling in LPS- or DMXAA-tolerized cells is a consequence 
of an event that occurs early in the signaling pathway, be-
cause IRF-3 dimers are detected within 15 min after agonist 
stimulation. Although we have shown that LPS and DMXAA 
seem to engage distinct signaling pathways, both lead to IRF-3 
activation via TBK1. Thus, it seems plausible that one signaling 
component tolerized by pretreatment with LPS or DMXAA 
is TBK1 itself. Studies are ongoing to address the role of TBK1 
expression levels and enzymatic activity in the induction of 
cross-tolerance by LPS and DMXAA.
During the course of these studies, we extended previous 
fi  ndings that demonstrated SA as an inhibitor of DMXAA. 
Although an inhibitory eff  ect of SA on DMXAA-induced 
TNF-α expression had been previously reported (8), our re-
sults identify a possible explanation for the role played by SA 
in DMXAA inhibition. Pretreatment of macrophages with SA 
blocked DMXAA-induced phosphorylation of IRF-3 at resi-
due S396, IRF-3 dimerization, and IFN-β expression (Fig. 5). 
However, all three events were unaff  ected by SA in LPS-
stimulated cells. These results support our conclusion that the 
pathways leading to IFN-β gene expression by these two 
stimuli diff  er.
In conclusion, we present data that fi  rmly establishes the 
clinically important VDA DMXAA as a potent and specifi  c 
activator of the TBK1–IRF-3 axis. The link between height-
ened activity of this signaling pathway and a systemic anti-
tumor response likely involves myriad and divergent events. 
However, by identifying a key signaling pathway with known 
antitumor potential as critical to the response to DMXAA, 
we hope to further our understanding of both the mechanism 
of action of this promising new chemotherapeutic agent as 
well as the role of the innate immune response in defending 
the host against cancer.JEM VOL. 204, July 9, 2007  1567
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MATERIALS AND METHODS
Mice. 5–6-wk-old C57BL/6J females were purchased from the Jackson 
Laboratory. IRF-3−/− mice were a gift of T. Taniguchi (University of Tokyo, 
Tokyo, Japan). IFN-β−/− mice (>N8 on a C57BL/6 background) were a gift 
of E. Fish (University of Toronto, Toronto, Canada). MyD88−/−/TRIF−/− 
mice were bred from MyD88−/− (64) and TRIF−/− (39) mice. IKKε−/− 
mice were generated at Millennium Pharmaceuticals. TBK1−/− mice were a 
gift of W.-C. Yeh (University of Toronto, Toronto, Canada) and were bred 
with TNFR1−/− mice at the University of Massachusetts Medical School. 
All experiments were conducted with Institutional Animal Care and Use 
Committee approval.
Reagents and virus.  DMXAA (sodium salt; 304 daltons) was synthesized at 
the Auckland Cancer Society Research Centre (65). Poly I:C (GE Healthcare) 
was used exogenously as a TLR3 agonist. For triggering intracellular RNA 
  helicases, poly I:C was transfected as follows: 10 μg/ml poly I:C was mixed with 
a transfection reagent (Fugene 6; Roche) at a ratio of 1:1 (volume/weight) in 
OptiMEM (Invitrogen) and incubated for 15 min before stimulation. Sendai 
virus was used at 200 hemagglutination U/ml. Protein-free E. coli K235 LPS 
(66) was used as a TLR4 agonist. SA was obtained from Sigma-Aldrich. C-
  terminal GST fusions of IRF-3 (wild-type aa 380–427 and IRF-3–A7 mutant 
in which amino acids S385, S386, S396, S398, S402, T404, and S405 were 
all mutated to alanine) were purifi  ed according to standard protocols (GE 
Healthcare). pAb to TBK1 (raised against the C terminus of human TBK1) 
was provided by T. Maniatis (Millenium Pharmaceuticals, Cambridge, MA). 
Anti-TBK1 mAb (IMG-139, raised against aa 563–577 of human TBK1) was 
obtained from Imgenex.
Cell culture. Thioglycollate-elicited mouse peritoneal macrophages were 
obtained and cultured as previously described (52). Bone marrow–derived macro-
phages were generated from bone marrow cells cultured in L929-conditioned 
media for 10 d and were examined by FACS and found to be >99% F4/80 
and CD11b double positive. Mouse macrophage-like RAW 264.7 cells were 
purchased from the American Type Culture Collection. Embryonic fi  broblasts 
from TBK1+/+ and TBK1−/− mice were a gift of W.-C. Yeh. RIG-I (50) and 
IPS-1 (36) knockout MEFs have been described elsewhere. Embryonic fi  bro-
blasts from IKKβ+/+ and IKKβ−/− mice were a gift of J. DiDonato (Cleveland 
Clinic, Cleveland, Ohio). RAW 264.7 macrophages and embryonic fi  broblasts 
were cultured in DMEM (BioWhittaker), supplemented with 10% (vol/vol) 
FBS (HyClone Laboratories), 10,000 U/ml penicillin, and 10,000 μg/ml 
streptomycin at 37°C in 5% CO2 in air. The endotoxin content in the medium 
was <0.01 EU/ml, according to the manufacturer’s specifi  cations. Only cells 
passaged ≤20 times were used.
Quantitative real-time PCR. Primers for detection of IFN-β, RANTES, 
TNF-α, and hypoxanthine phosphoribosyltransferase (HPRT) mRNAs were 
designed using the Primer Express program (version 2.0; Applied Biosystems). 
31.25 ng of total cDNA was used as starting material for real-time PCR quan-
titation with SYBR Green (Applied Biosystems) on a real-time PCR system 
(7900HT; Applied Biosystems). Ct values were compared using the ∆∆-Ct 
method using HPRT as a housekeeping gene (67).
Cytokine analysis. IFN-β protein in cell culture supernatants was measured 
using a custom ELISA originally described elsewhere (68), with few modifi  -
cations. In brief, 96-well polystyrene plates (Maxisorp; Nunc International) 
were coated overnight with a 1:4,000 dilution of rat anti–mouse IFN-β mAb 
(Yamasa) in 0.1 M sodium carbonate at 4°C. Plates were blocked with 10% 
FCS in 1× PBS for 2 h at room temperature. Samples and a mouse IFN-β 
standard (National Institutes of Health [NIH]) were added to wells and incu-
bated overnight at 4°C. Plates were washed 3 times with 1% FCS/PBS-T, 
followed by incubation with a 1:2,000 dilution of rabbit anti–mouse IFN-β 
pAb (PBL Biomedical Laboratories) in 10% FCS-PBS overnight at 4°C. Wells 
were washed 3 times, followed by incubation with a 1:2,000 dilution of goat 
anti–rabbit horseradish peroxidase (HRP; Cell Signaling Technologies) in 
10% FCS-PBS for 1 h at room temperature. Plates were washed 3 times and 
developed with TMB substrate (KPL). The reaction was stopped by addition of 
1 N H2SO4, and plates were read at 450 nm. For quantifi  cation of RANTES 
and TNF-α, Luminex bead-based colorimetric assays were performed by the 
Cytokine Core Laboratory (University of Maryland, Baltimore).
EMSA. Oligonucleotides containing the DNA sequence corresponding to 
the prototypic NF-κB binding site in the mouse Igκ light chain gene en-
hancer (5′-A  G  C  T  C  A  G  A  G  G  G  G  A  C  T  T  T  C  C  G  A  G  A  G  -3′ and 3′-G  T  C  T  C  C-
C  C  T  G  A  A  A  G  G  C  T  C  T  C  T  C  G  A  -5′; NF-κB binding sites are bolded) was 
annealed in a buff  er containing 10 mM Tris HCl (pH 8), 50 mM NaCl, 10 mM 
MgCl2, and 1 mM dithiothreitol. 50 ng of the annealed oligonucleotide 
was labeled with an oligolabeling kit, according to the manufacturer’s instruc-
tions (GE Healthcare). After the labeling, unincorporated nucleotides were 
removed with a Bio-spin column (Bio-Rad Laboratories). For each DNA–
protein binding reaction, 5 μg of nuclear extract was used in the presence of 
0.2 ng of labeled probe in a 25-μl reaction mixture. The DNA–protein bind-
ing buff  er contained 1 μg of (poly dI:dC) per ml, 10% glycerol, 10 mM Tris 
HCl (pH 8), 1 mM EDTA, 40 mM KCl, and 1 mM dithiothreitol. All 
DNA–protein binding reactions were allowed to proceed at room temperature 
for 30 min. Samples were loaded onto a nondenaturing 4% polyacrylamide 
gel. After electrophoresis, the gel was transferred to chromatography paper 
and dried at 80°C. The dried gel was exposed for signal development to fi  lm 
(XAR-5; Kodak) in the presence of an intensifying screen at −70°C.
Antibodies and native PAGE. Polyclonal rabbit anti–mouse IκBα was 
purchased from Santa Cruz Biotechnology, Inc. Rabbit anti–mouse MAPK 
pAbs and rabbit anti–human phospho–IRF-3 pAbs were purchased from 
Cell Signaling Technologies. Rabbit anti–mouse IRF-3 pAb was purchased 
from Zymed Laboratories. Anti-TBK1 was a gift of T. Maniatis. Native 
PAGE for the detection of IRF-3 dimers was performed as previously de-
scribed (69). In brief, thioglycollate-elicited peritoneal macrophages were 
lysed after stimulation with either LPS or DMXAA, as indicated in the fi  g-
ures. Proteins were separated in the absence of SDS in 7.5% Tris-Glycine 
gels (Bio-Rad Laboratories) and transferred to polyvinylidene difl  uoride. 
Membranes were probed with a 1:250 dilution of rabbit anti–mouse IRF-3 
for 1 h at room temperature. Goat anti–rabbit IgG-HRP at a 1:2,000 dilution 
was used as the secondary antibody. Blots were developed with ECL Plus 
(GE Healthcare).
In vitro kinase assays. Bone marrow–derived macrophages were diff  er-
entiated ex vivo, plated, allowed to rest overnight, and stimulated with 
medium alone, 200 ng/ml LPS, or 100 μg/ml DMXAA for 90 min. Cells 
were lysed, and 500 μg of whole-cell lysate was subjected to immunoprecipita-
tion with anti-TBK1 pAb together with protein G beads (Sigma-Aldrich). 
Immunoprecipitates were washed three times and examined for TBK1 protein 
levels by Western blotting with anti-TBK1 mAb and TBK1 kinase activity 
by an in vitro kinase assay. For in vitro kinase assays, TBK1 immunoprecipi-
tates were incubated with a wild-type C-terminal (aa 380–427) GST–IRF-3 
or GST–IRF-3–A7 mutant (1 μg). Recombinant TBK1 and IKKβ were 
also examined for their ability to phosphorylate wild-type GST–IRF-3 and 
the GST–IRF-3–A7 mutant (40 ng). GST-IκBα was used as a positive con-
trol for IKKβ kinase activity. Kinase reactions were performed in kinase 
buff  er (20 mM Hepes, 50 mM NaCl, 10 mM MgCl2, 20 mM β-glycerol 
phosphate, 1 mM sodium orthovanadate, 1 mM dithiothreitol) for 30 min at 
30°C in the presence of γ-[32P]ATP using methods previously outlined (44). 
Proteins were separated by SDS-PAGE and visualized via autoradiography.
Online supplemental material.  Table S1 shows the results of a micro array 
analysis performed using Aff  ymetrix mouse array 430A_2 exposed to total 
RNA prepared from C57BL/6J or IFN-β−/− macrophages that had been 
treated with medium alone or DMXAA for 3 h. Fold induction was calcu-
lated using GeneChip operating software (Aff  ymetrix). A ≥3-fold increase or 
decrease between inducible and basal mRNA levels was set as the criteria for 
inclusion of a gene as modulated. Complete microarray data have been depos-
ited in the National Center for Biotechnology Information Gene   Expression 1568  DMXAA IS A SPECIFIC ACTIVATOR OF TBK1 | Roberts et al.
Omnibus under accession no. GSE7194. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20061845/DC1.
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